Zhou et al. screened 1,280 compounds Collection for CLK3 inhibition and demonstrated that tacrine hydrochloride could be repurposed as a CLK3 inhibitor for cholangiocarcinoma (CCA) treatment [160]. This evidence concerns the gene CLK3 and cholangiocarcinoma.